DDInter1042 DDInter1081
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Lithium carbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lithium carbonate may lead to a major life threatening interaction when taken with Cisapride
Lithium carbonate may lead to a major life threatening interaction when taken with Ivosidenib